Sunday, February 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The Distribution of New Cases in the US has Shifted

The distribution of new cases in the US has shifted from the Northeast to the Southern and Western states.

Pink – The Northeast includes New England (MA, CT, RI, VT, NH, ME).

Maroon – Mid-Atlantic states (NY, NJ, PA).

Light Gray – East North Central states (MI, OH, IN, IL, WI).

Dark Gray – West North Central states (MN, IA, MO, ND, SD, NE, KS).

Navy Blue – South Atlantic states (WV, MD, DE, VA, NC, SC, GA, FL).

Baby Blue – East South Central states (KY, TN, MS, AL)

Sea Blue – West South Central states (TX, OK, AR, LA).

Dark Green – Mountain states (MT, ID, WY, NV, UT, CO, NM, AZ)

Light Green – Pacific states (CA, OR, WA).

Source: John Hopkins, McKinsey & Co.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!